These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24588460)

  • 1. Predicting success: optimizing phase II ALS trials for the transition to phase III.
    Berry JD; Cudkowicz ME; Shefner JM
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Mar; 15(1-2):1-8. PubMed ID: 24588460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA; Mozaffar T
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.
    Berry JD; Miller R; Moore DH; Cudkowicz ME; van den Berg LH; Kerr DA; Dong Y; Ingersoll EW; Archibald D
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Apr; 14(3):162-8. PubMed ID: 23323713
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
    [No Abstract]   [Full Text] [Related]  

  • 6. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?
    Atassi N; Beghi E; Blanquer M; Boulis NM; Cantello R; Caponnetto C; Chiò A; Dunnett SB; Feldman EL; Vescovi A; Mazzini L;
    Cytotherapy; 2016 Dec; 18(12):1471-1475. PubMed ID: 27720637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities for improving therapy development in ALS.
    Bruijn L; Cudkowicz M;
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Jun; 15(3-4):169-73. PubMed ID: 24472060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis.
    Sanjak M; Salachas F; Frija-Orvoen E; Theys P; Hutchinson D; Verheijde J; Pianta T; Stewart H; Brooks BR; Meininger V; Douillet P;
    Amyotroph Lateral Scler; 2010 Aug; 11(4):383-8. PubMed ID: 20192884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
    Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
    Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 15. An efficient multi-stage, single-arm Phase II futility design for ALS.
    Palesch YY; Tilley BC
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():55-6. PubMed ID: 15512874
    [No Abstract]   [Full Text] [Related]  

  • 16. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we eliminate placebo in ALS clinical Trials?
    Simmons Z
    Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.